Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
GSK PLC (GSK)
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-11-04
$50.41-1.45%
Close 2026-11-05 · 1-day change
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
3.86 → 3.77 EPS · FY ending Dec 31, 2027 · 7 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 7 to 7; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for GSK yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
EPS near $5.12 in FY27 | Earnings per share are about $5 next year. | Under Pressure | EPS falls below $4.50 in FY27 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is best described as a healthcare-sector exposure with an insufficiently established company-specific thesis. The thesis state is unclear, and confidence is low.
The snapshot gives no valuation or expectations data, so it does not show whether GSK is cheap, fair, or expensive versus peers, or what the market already assumes. The muted price reaction does not resolve that gap.
The healthcare sector backdrop has strengthened, which may support the near-term setting for GSK, but the snapshot provides too little recent company financial history to assess its fundamental trajectory. Near-term miss risk is described as low, though the evidence notes a deep past miss and recent peer misses.
The near-term sector setting may depend on whether bellwethers such as LLY, JNJ, and ABBV keep delivering strong results and guidance. A weakening jobs report could also increase recession concerns, while company-specific execution remains hard to judge from the limited evidence.
For the next 1 to 3 years, the evidence supports only a cautious, incomplete read: sector conditions have improved, but GSK’s own financial trajectory and valuation are not established here. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A supporting condition in GSK PLC's published investment case. The stated target is integration completed and contributing to revenue by FY27. |
| Intact |
| Acquisition fails to contribute or is divested by FY27 |
Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
annual revenue growth near 5% in FY27 | A primary condition in GSK PLC's published investment case. The stated target is >=5% YoY revenue growth. | Intact | YoY revenue growth falls below 3% in FY27 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$3.92 → $3.77 · observed estimates
$35.73B → $35.56B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $3.92 | $35,732,354,426 | 6 / 13 |
| 2026-07-25 | $3.92 | $35,732,354,426 | 6 / 13 |
| 2026-07-26 | $5.16 | $35,637,050,330 | 3 / 19 |
| 2026-07-27 | $3.92 | $35,741,365,341 | 6 / 13 |
| 2026-07-28 | $5.16 | $35,652,379,320 | 3 / 19 |
| 2026-07-29 | $5.16 | $35,652,379,320 | 3 / 19 |
| 2026-07-30 | $5.16 | $35,652,379,320 | 3 / 19 |
| 2026-07-31 | $5.14 | $35,623,096,920 | 3 / 19 |
| 2026-08-01 | $3.90 | $35,657,916,002 | 6 / 14 |
| 2026-08-02 | $3.90 | $35,657,916,002 | 6 / 14 |
| 2026-08-03 | $5.14 | $35,618,321,400 | 3 / 19 |
| 2026-08-04 | $5.14 | $35,618,321,400 | 3 / 19 |
| 2026-08-05 | $5.14 | $35,623,806,290 | 3 / 19 |
| 2026-08-06 | $5.14 | $35,623,806,290 | 3 / 19 |
| 2026-08-07 | $3.88 | $35,709,293,457 | 6 / 14 |
| 2026-08-08 | $5.14 | $35,628,626,770 | 3 / 19 |
| 2026-08-09 | $5.14 | $35,628,626,770 | 3 / 19 |
| 2026-08-10 | $5.14 | $35,628,626,770 | 3 / 19 |
| 2026-08-12 | $5.14 | $35,595,324,510 | 3 / 19 |
| 2026-08-13 | $5.14 | $35,595,324,510 | 3 / 19 |
| 2026-08-14 | $3.88 | $35,709,293,457 | 6 / 14 |
| 2026-08-15 | $3.88 | $35,709,293,457 | 6 / 14 |
| 2026-08-16 | $3.88 | $35,709,293,457 | 6 / 14 |
| 2026-08-17 | $3.88 | $35,709,293,457 | 6 / 14 |
| 2026-08-18 | $3.88 | $35,709,293,457 | 6 / 14 |
| 2026-08-19 | $3.88 | $35,709,293,457 | 6 / 14 |
| 2026-08-20 | $3.84 | $35,719,007,820 | 6 / 14 |
| 2026-08-21 | $3.84 | $35,719,007,820 | 6 / 14 |
| 2026-08-22 | $3.84 | $35,719,007,820 | 6 / 14 |
| 2026-08-23 | $3.84 | $35,719,007,820 | 6 / 14 |
| 2026-08-24 | $3.84 | $35,719,007,820 | 6 / 14 |
| 2026-08-25 | $3.84 | $35,691,611,643 | 6 / 14 |
| 2026-08-26 | $3.84 | $35,691,611,643 | 6 / 14 |
| 2026-08-27 | $3.84 | $35,691,611,643 | 6 / 14 |
| 2026-08-28 | $3.84 | $35,691,611,643 | 6 / 14 |
| 2026-08-29 | $3.84 | $35,715,564,721 | 6 / 14 |
| 2026-08-30 | $3.84 | $35,715,564,721 | 6 / 14 |
| 2026-08-31 | $3.84 | $35,715,564,721 | 6 / 14 |
| 2026-09-01 | $3.84 | $35,715,564,721 | 6 / 14 |
| 2026-09-02 | $3.83 | $35,715,564,721 | 6 / 14 |
| 2026-09-03 | $3.83 | $35,682,494,809 | 6 / 14 |
| 2026-09-04 | $3.83 | $35,682,494,809 | 6 / 14 |
| 2026-09-05 | $3.83 | $35,693,199,732 | 6 / 14 |
| 2026-09-06 | $3.83 | $35,693,199,732 | 6 / 14 |
| 2026-09-07 | $3.83 | $35,693,199,732 | 6 / 14 |
| 2026-09-08 | $3.83 | $35,693,199,732 | 6 / 14 |
| 2026-09-09 | $3.83 | $35,715,550,345 | 6 / 14 |
| 2026-09-10 | $3.83 | $35,715,550,345 | 6 / 14 |
| 2026-09-11 | $3.83 | $35,736,807,231 | 6 / 14 |
| 2026-09-12 | $3.83 | $35,736,807,231 | 6 / 14 |
| 2026-09-13 | $3.83 | $35,736,807,231 | 6 / 14 |
| 2026-09-14 | $3.84 | $35,736,807,231 | 6 / 14 |
| 2026-09-15 | $3.83 | $35,719,069,622 | 6 / 14 |
| 2026-09-16 | $3.84 | $35,759,581,402 | 6 / 14 |
| 2026-09-17 | $3.84 | $35,759,581,402 | 6 / 14 |
| 2026-09-18 | $3.84 | $35,759,581,402 | 6 / 14 |
| 2026-09-19 | $3.84 | $35,759,581,402 | 6 / 14 |
| 2026-09-20 | $3.85 | $35,811,144,021 | 6 / 14 |
| 2026-09-21 | $3.85 | $35,733,199,109 | 6 / 14 |
| 2026-09-22 | $3.85 | $35,734,558,663 | 7 / 14 |
| 2026-09-23 | $3.85 | $35,797,473,862 | 7 / 14 |
| 2026-09-24 | $3.87 | $35,939,670,175 | 7 / 14 |
| 2026-09-25 | $3.86 | $35,954,499,343 | 7 / 14 |
| 2026-09-26 | $3.86 | $35,949,151,060 | 7 / 14 |
| 2026-09-27 | $3.86 | $35,949,151,060 | 7 / 14 |
| 2026-09-28 | $3.87 | $35,995,375,504 | 7 / 14 |
| 2026-09-29 | $3.87 | $36,056,976,261 | 7 / 14 |
| 2026-09-30 | $3.87 | $36,040,422,052 | 7 / 14 |
| 2026-10-01 | $3.87 | $36,036,058,822 | 7 / 14 |
| 2026-10-02 | $3.87 | $36,075,536,922 | 7 / 14 |
| 2026-10-03 | $3.86 | $36,064,175,631 | 7 / 14 |
| 2026-10-04 | $3.86 | $36,062,393,467 | 7 / 14 |
| 2026-10-05 | $3.86 | $36,082,601,927 | 7 / 14 |
| 2026-10-06 | $3.85 | $35,993,869,050 | 7 / 14 |
| 2026-10-07 | $3.84 | $35,952,682,976 | 7 / 14 |
| 2026-10-08 | $3.84 | $35,945,386,452 | 7 / 14 |
| 2026-10-09 | $3.83 | $35,895,002,038 | 7 / 14 |
| 2026-10-10 | $3.83 | $35,895,002,038 | 7 / 14 |
| 2026-10-11 | $3.82 | $35,784,786,046 | 7 / 15 |
| 2026-10-12 | $3.82 | $35,799,556,910 | 7 / 15 |
| 2026-10-13 | $3.83 | $35,802,541,098 | 7 / 15 |
| 2026-10-14 | $3.83 | $35,778,439,164 | 7 / 14 |
| 2026-10-15 | $3.82 | $35,725,150,003 | 7 / 14 |
| 2026-10-16 | $3.82 | $35,731,723,323 | 7 / 14 |
| 2026-10-17 | $3.82 | $35,731,723,323 | 7 / 14 |
| 2026-10-18 | $3.82 | $35,736,504,805 | 7 / 14 |
| 2026-10-19 | $3.82 | $35,736,504,805 | 7 / 14 |
| 2026-10-20 | $3.82 | $35,727,300,569 | 7 / 14 |
| 2026-10-21 | $3.82 | $35,718,733,321 | 7 / 14 |
| 2026-10-22 | $3.82 | $35,718,733,321 | 7 / 14 |
| 2026-10-23 | $3.82 | $35,742,815,447 | 7 / 14 |
| 2026-10-24 | $3.82 | $35,742,815,447 | 7 / 14 |
| 2026-10-25 | $3.82 | $35,742,815,447 | 7 / 14 |
| 2026-10-26 | $3.82 | $35,742,815,447 | 7 / 14 |
| 2026-10-27 | $3.82 | $35,742,815,447 | 7 / 14 |
| 2026-10-28 | $3.82 | $35,747,298,076 | 7 / 14 |
| 2026-10-29 | $3.78 | $35,554,601,862 | 7 / 14 |
| 2026-10-30 | $3.78 | $35,592,455,703 | 7 / 14 |
| 2026-10-31 | $3.78 | $35,612,903,309 | 7 / 14 |
| 2026-11-01 | $3.78 | $35,612,903,309 | 7 / 14 |
| 2026-11-02 | $3.78 | $35,612,903,309 | 7 / 14 |
| 2026-11-03 | $3.77 | $35,545,204,066 | 7 / 14 |
| 2026-11-04 | $3.77 | $35,563,038,286 | 7 / 14 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 3 Buy / Strong Buy · 5 Hold · 1 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 1 recorded
0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.